Document Detail

Vaccination against drug resistance in HIV infection.
MedLine Citation:
PMID:  18251699     Owner:  NLM     Status:  MEDLINE    
HIV-1 resistance to currently employed antiretroviral drugs and drug-associated adverse reactions and toxicity point to a need for additional measures to control HIV-1 replication in HIV-infected patients. The immune system of HIV-infected individuals mount an immune response against the regions harboring drug-resistance mutations, sometimes stronger than that against the parental wild-type sequences. A potent cross-reactive immune response against drug-resistant pol proteins can suppress the replication of drug-escaping HIV. This suggests the possibility for a vaccination against existing and anticipated drug-resistant HIV variants. If successful, therapeutic vaccines against drug resistance would ease the therapeutic modalities and limit the spread of drug-resistant HIV. A better understanding of the complex interactions between patterns of drug-resistance mutations, immune responses against these mutations and their antigen presentation by particular human lymphocyte antigen alleles could help to tailor these vaccines after new drugs/new mutations. In this review, we describe the developments in the field of immunization against mutations conferring drug resistance and evaluate their prospects for human vaccination.
Andreas Boberg; Maria Isaguliants
Related Documents :
16883349 - Treatment of chronic hepatitis b.
15183339 - Designing anti-aids drugs targeting the major mechanism of hiv-1 rt resistance to nucle...
12531179 - Fitness of drug resistant hiv-1: methodology and clinical implications.
2202409 - Genital herpes--when and how to treat.
24028619 - In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and d...
12367719 - Polymorphisms of cytotoxic t-lymphocyte (ctl) and t-helper epitopes within reverse tran...
15640379 - Expression and function of abcb1 and abcg2 in human placental tissue.
25009069 - Silk fibroin rods for sustained delivery of breast cancer therapeutics.
18819029 - Glutaraldehyde cross-linked chitosan microspheres for controlled delivery of zidovudine.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert review of vaccines     Volume:  7     ISSN:  1744-8395     ISO Abbreviation:  Expert Rev Vaccines     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-02-06     Completed Date:  2008-08-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101155475     Medline TA:  Expert Rev Vaccines     Country:  England    
Other Details:
Languages:  eng     Pagination:  131-45     Citation Subset:  IM    
Swedish Institute for Infectious Disease Control, 171 82 Solna, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
AIDS Vaccines / administration & dosage,  therapeutic use*
Anti-HIV Agents / therapeutic use
Cross Reactions
Drug Administration Schedule
Drug Resistance, Viral* / genetics
HIV / genetics
HIV Infections / drug therapy,  immunology,  therapy*,  virology
Reg. No./Substance:
0/AIDS Vaccines; 0/Anti-HIV Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Murine models for HIV vaccination and challenge.
Next Document:  JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.